

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PHY

Applicant(s):

Adamou et al

Serial No:

10/067,385

Art Unit: 1645

Filed:

5 February 2002

Examiner: Devi, S.

Title:

Streptococcus Pneumoniae Proteins and Vaccines

Docket No:

469290-589

6 June 2003

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application. In addition, a supplemental disclosure statement has been filed citing related co-pending applications.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits. No fee or statement is required.

Serial No: 10/067,385 Filed: 5 February 2002

91.8	97(C) This int	specified in paragraph (b) above, but before the mailing date of either:				
	(1)	A Final Action or under 37 CFR §1.113; OR				
	(2)	A Notice of Allowance under 37 CFR §1.311; AND				
	is acc	companied by either: (check one)				
		The statement as specified in 37 CFR §1.97(e) set out below; OR				
		The fee of \$ 180.00 under 37 CFR §1.17(p).				
§1.97(d)	of eit					
	(1)	a Final Action or under 37 CFR §1.113; OR				
	(2)	A Notice of Allowance under 37 CFR §1.311;				
BUT filed on or before payment of the Issue Fee; AND						
		companied by:				
	(1)	The statement as specified in 37 CFR §1.97(e) as set forth below; AND				
	(2)	Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,				
	(3)	The petition fee of \$130.00 set out in 37 CFR §1.17(i).				
§1.97(e)	The undersig	ned Attorney hereby states that:				
	Statement win a counter	of information contained in this Information Disclosure was cited in a communication from a foreign patent office part foreign application not more than three months prior late of this Information Disclosure Statement;				
	no item of	information contained in this Information Disclosure as cited in a communication from a foreign patent office				
	in a counte undersigned any individu	erpart foreign application, or to the knowledge of the Attorney after making reasonable inquiry, was known to all designated in 37 CFR §1.56(c) more than three or to the filing date of the Information Disclosure				

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

Serial No: 10/067,385 Filed: 5 February 2002

## FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

> Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Alan J. Grant , Esq.

Date'

Respectfully submitted,

Plan & Grant

Alan J. Grant, Esq. Reg. No. 33,389

(cg. 110. 00,000

CARELLA, BYRNE BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN

Six Becker Farm Road Roseland, NJ-07068 Phone: 973-994-1700

Fax: 973-994-1744

IP.E V					Page_	of	1		
JUN 0 9 2003	<b>5</b> /	Form PTO-1449 ON DISCLOSURE S	TATEMENT	Atty. Docket: 469201-589		Serial No. 10/067,385			
TRADEN		O.V DIOCEOUTE O	<u> </u>	Applicant: John Ac	iamou	<u> </u>			
			Filing Date: 5 February 2002		Group: 1645				
			U.S. PA	TENT DOCUMENTS					
Examiner Initial		Document Number	Date	Name	Class	Sub- Class	Filing Date		
	Al								
	B1	<u> </u>					<u> </u>		
•			FORÈIGN	PATENT DOCUMEN	NTS				
Examiner Initial		Document Number	Date	Country	Class	Sub- Class	Translation		
-	Cı	WO 98/18930	7 May 1998	PCT					
	D1	WO 00/06738	10 February 2000	PCT					
		0	THER (Including Aut	hor, Title, Date, Perti	nent Pages, etc.)				
	E1	Nayak et al., Infection and Immunity, 66:3744-3751 (1998)							
	F1	Lazar et al., Mol. Cellular Biol. 8:1247-1252 (1988)							
	GI	Burgess et al., J. Cell. Biol. 111:2129-2138 (1990)							
	ні	Bowie et al., Science 247:1306-1310 (1990)							
	I1						<u> </u>		
	J1								
	K1								
	L1								
	M1				·				
	NI	<u> </u>							
Examiner:					Date Conside	Date Considered:			
EXAMINER	<b>:</b> :		nce considered, whether ance and not considered				w line through citation if of Applicant.		

#174351 v1